<DOC>
	<DOCNO>NCT00771563</DOCNO>
	<brief_summary>Rationale : number recent phase III randomize trial show survival benefit treatment subcutaneous low-molecular weight heparin patient advance solid malignancy . The survival advantage observe study persist month active treatment LMWHs . Therefore survival advantage think due effect LMWHs tumor cell biology . First line treatment advance NSCLC patient Cisplatin + Docetaxel combination widely study , amongst active treatment currently available . The occurrence grade 3/4 thrombopenia several phase III trials 0-3 % range , make ideal chemotherapy regimen combine LMWHs treatment advance NSCLC .</brief_summary>
	<brief_title>Enoxaparin Low Molecular Weight Heparin ( LMWH ) Advanced Non Small Cell Lung Cancer : Effect Survival Symptom Control Patients Undergoing First Line Chemotherapy ( SYRINGES )</brief_title>
	<detailed_description>Purpose : aim study evaluate potential beneficial antitumoral effect LMWH enoxaparin patient locally advance metastatic NSCLC determine time progression , overall survival symptom control . LMWH add first line cisplatin-based chemotherapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Locally advanced metastatic NSCLC ( stage IIIB IV ) Patients candidate radical combine modality treatment highdose radiation therapy At least one measurable lesion accord RECIST criterion Good performance status Adequate haematological , renal liver function Written inform consent Previous chemotherapy NSCLC Brain metastasis History cerebral haemorrhage , neurosurgery within 3 previous month surgery within past 6 month Indication anticoagulant therapy , thrombolytic therapy antiplatelet therapy cardiovascular disease Concomitant therapy antiangiogenesis agent Contraindication LMWH Life expectancy &lt; 3 month Serious concomitant systemic disease , uncontrolled arterial hypertension , active peptic ulcer condition permit study treatment followup require comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>Low Molecular Weight Heparin</keyword>
</DOC>